MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
US Market
Holding MLTX?
Track your performance easily

MoonLake Immunotherapeutics (MLTX) Ownership - Who Owns MoonLake Immunotherapeutics?

296 Followers

MoonLake Immunotherapeutics (MLTX) Ownership Overview

26.78%14.05%0.74%0.52%57.91%
26.78% Insiders
0.74% Other Institutional Investors
0.52% ETFs
57.91% Public Companies and
Individual Investors
The ownership structure of MoonLake Immunotherapeutics (MLTX) stock is a mix of institutional, retail, and individual investors. Approximately 15.31% of the company’s stock is owned by Institutional Investors, 26.78% is owned by Insiders, and 57.91% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Oct 08, 2024
Simon Sturge
Director
xxxxxxxxxxxxx
$9186120
Oct 08, 2024
Bvf Partners Lp Il
Director, >10% Owner
xxxxxxxxxxxxx
$100000000

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2024
xxxxxxxxxxxxx
$615580
Jun 30, 2024
xxxxxxxxxxxxx
$9968746

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
8,494,151Insider14.17%399,225,097
2,982,814Insider4.74%140,192,258
2,967,554Insider4.72%139,475,038
1,287,768Insider2.05%60,525,096
1,230,361Institution1.96%57,826,967
1,049,003Institution1.67%49,303,141
1,026,276Institution1.63%48,234,972
749,741Institution1.19%35,237,827
626,069Institution1.00%29,425,243
548,604Institution0.87%25,784,388

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
1,230,361Institution1.96%57,826,967
1,049,003Institution1.67%49,303,141
1,026,276Institution1.63%48,234,972
749,741Institution1.19%35,237,827
626,069Institution1.00%29,425,243
548,604Institution0.87%25,784,388
524,962Institution0.83%24,673,214
519,789Institution0.83%24,430,083
515,575Institution0.82%24,232,025
305,983Institution0.49%14,381,201

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
73,366Institution0.12%3,699,114
44,546Institution0.07%2,067,825
21,775Institution0.03%1,373,031
25,756Institution0.04%1,241,182
18,864Institution0.03%882,647
17,686Institution0.03%852,288
15,825Institution0.03%797,897
13,590Institution0.02%638,730
13,056Institution0.02%610,890
10,080Institution0.02%473,760

FAQ

Who Owns MoonLake Immunotherapeutics (MLTX)?
According to the latest TipRanks data, approximately 0.74% of the company's stock is held by institutional investors, 26.78% is held by insiders, and 57.91% is held by retail investors.
    What percentage of MoonLake Immunotherapeutics (MLTX) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 0.74% of MoonLake Immunotherapeutics (MLTX) stock is held by institutional investors.
      What percentage of MoonLake Immunotherapeutics (MLTX) stock is held by retail investors?
      According to the latest TipRanks data, approximately 57.91% of MoonLake Immunotherapeutics (MLTX) stock is held by retail investors.
        Who owns the most shares of MoonLake Immunotherapeutics (MLTX)?
        Chen Bihua owns the most shares of MoonLake Immunotherapeutics (MLTX).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis